-
1 Comment
Guizhou Yibai Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 1.9% above its 200 day moving average.
From a valuation standpoint, the stock is 86.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.
Guizhou Yibai Pharmaceutical Co., Ltd's total revenue rose by 6.8% to $960M since the same quarter in the previous year.
Its net income has increased by 28.8% to $70M since the same quarter in the previous year.
Finally, its free cash flow fell by 522.4% to $-105M since the same quarter in the previous year.
Based on the above factors, Guizhou Yibai Pharmaceutical Co., Ltd gets an overall score of 4/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | CNE000001H03 |
| Exchange | SHG |
| CurrencyCode | CNY |
| Market Cap | 3B |
|---|---|
| PE Ratio | None |
| Target Price | 6.55 |
| Beta | 0.41 |
| Dividend Yield | None |
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatism, digestive system, pediatric, gynecological, anti-infection, anti-inflammatory, analgesic, and other diseases. The company was founded in 1995 and is based in Guiyang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600594.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
